Differential expression of topoisomerase IIα protein in salivary gland carcinomas: Histogenetic and prognostic implications

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Maruya, Shin Ichiro ^a,b   Shirasaki, Takashi ^a   Nagaki, Takahiko ^a   Kakehata, Seiji ^a   Kurotaki, Hidekachi ^c   Mizukami, Hiroki ^a   Shinkawa, Hideichi ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b International University of Health and Welfare Mita Hospital   (Japan)

^c Odate Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ACINAR CELL CARCINOMA; ADENOCARCINOMA; ADENOID CYSTIC CARCINOMA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; CHILD; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPHOEPITHELIOMA; MAJOR CLINICAL STUDY; MALE; MYOEPITHELIOMA; PLEOMORPHIC ADENOMA; PROGNOSIS; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; WARTHIN TUMOR; BIOSYNTHESIS; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; SALIVARY GLAND TUMOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, ADENOID CYSTIC; CHILD; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SALIVARY GLAND NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 62749108039     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-72     Document Type: Article

References (27)

1. Spiro RH Management of malignant tumors of the salivary glands Oncology 1998, 12:671-680. 9597678
2. Sternberg SS Histopathology for pathologists Philadelphia: Lippincott-Raven Press 1997, 405-425.
3. Szanto PA Luna MA Tortoledo ME White RA Histologic grading of adenoid cystic carcinoma of the salivary glands Cancer 1984, 15:1062-1069. 10.1002/1097-0142(19840915)54:6<1062::AID-CNCR2820540622>3.0.CO;2-E
4. Laurie SA Licitra L Systemic therapy in the palliative management of advanced salivary gland cancers J Clin Oncol 2006, 24:2673-2678.10.1200/ JCO.2005.05.3025 16763282
5. Wang JC Cellular roles of DNA topoisomerases: A molecular perspective Nat Rev Mol Cell Biol 2002, 3:430-440. 10.1038/nrm831 12042765
6. Kellner U Sehested M Jensen PB Gieseler F Rudolph P Culprit and victim-DNA topoisomerase II Lancet Oncol 2002, 3:235-243. 10.1016/ S1470-2045(02)00715-5 12067686
7. Mano MS Rosa DD De Azambuja E Ismael GF Durbecq The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours Cancer Treat Rev 2007, 33:64-77. 10.1016/ j.ctrv.2006.10.001 17113234
8. Glisson B Colevas AD Haddad R Krane J El-Naggar A Kies M Costello R Summey C Arquette M Langer C Amrein PC Posner M HER2 expression in salivary gland carcinomas: Dependence on histological subtype Clin Cancer Res 2004, 10:944-946. 10.1158/1078-0432.CCR-03-0253 14871971
9. Di Leo A Gancberg D Larsimont D Tanner M Jarvinen T Rouas G Dolci S Leroy JY Paesmans M Isola J Piccart MJ HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 2002, 8:1107-1116. 12006526
10. Coon JS Marcus E Gupta-Burt S Seelig S Jacobson K Chen S Renta V Fronda G Preisler HD Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 2002, 8:1061-1067. 11948114
11. Cardoso F Durbecq V Larsimont D Paesmans M Leroy JY Rouas G Sotiriou C Renard N Richard N Richard V Piccart MJ Di Leo A Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-α gene amplification and protein overexpression in locally advanced/metastatic breast cancer Int J Oncol 2004, 24:201-209. 14654958
12. Barnes L International Academy of Pathology, World Health Organization, International Agency for Research on Cancer. Pathology and genetics of head and neck tumours Lyon: IARC Press 2005
13. Kuropkat C Rudolph P Parwaresch R Werner JA Ki-Si-a prognostic marker for hypopharyngeal carcinoma with potential predictive value for response to chemotherapy Anticancer Res 2003, 23:3965-3970. 14666704
14. Ho DM Hsu CY Ting LT Chiang H MIB-1 and DNA topoisomerase IIα could be helpful for predicting long-term survival of patients with glioblastoma Am J Clin Pathol 2003, 119:715-722. 10.1309/ UN4WV65UH94JEWUV 12760291
15. Fritz P Cabrera CM Dippon J Gerteis A Simon W Aulitzky WE Kuip van der H c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: A retrospective study Breast Cancer Res 2005, 7:R374-384. 1143560 15987433 10.1186/ bcr1012
16. Lewis JE Olsen KD Sebo TJ Carcinoma ex pleomorphic adenoma: Pathologic analysis of 73 cases Hum Pathol 2001, 32:596-604. 10.1053/ hupa.2001.25000 11431714
17. Tortoledo ME Luna MA Batsakis JG Carcinoma ex pleomorphic adenoma and malignant mixed tumors. Histomorphologic indexes Arch Otolaryngol 1984, 110:172-176. 6322732
18. Coon JS Marcus E Gupta-Burt S Seelig S Jacobson K Chen S Renta V Fronda G Preisler HD Amplification and overexpression of topoisomerase IIα predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 2002, 8:1061-1067.11948114
19. Braybrooke JP Levitt NC Joel S Davis T Madhusudan S Turley H Wilner S Harris AL Talbot DC Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIα expression Clin Cancer Res 2003, 9:4682-4688. 14581337
20. Nguyen LH Black MJ Hier M Chauvin P Rochon L HER2/neu and Ki-67 as prognostic indicators in mucoepidermoid carcinoma of salivary glands J Otolaryngol 2003, 32:328-331. 10.2310/7070.2003.11438 14974865
21. Prat A Parera M Reyes V Peralta S Cedres S Andreu J Huquet P del Campo JM Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy Head Neck 2007, 30:680-683. 10.1002/hed.20714
22. Maruya S Kurotaki H Shimoyama N Kaimori M Shinkawa H Yagihashi S Expression of p16 protein and hypermethylation status of its promoter gene in adenoid cystic carcinoma of the head and neck ORL J Otorhinolaryngol Relat Spec 2003, 65:26-32. 12624503
23. Maruya S Kurotaki H Wada R Saku T Shinkawa H Yagihashi S Promoter methylation and protein expression of the E-cadherin gene in the clinicopathologic assessment of adenoid cystic carcinoma Mod Pathol 2004, 17:637-645. 10.1038/modpathol.3800104 15044918
24. Norberg-Spaak L Dardick I Ledin T Adenoid cystic carcinoma: Use of cell proliferation, BCL-2 expression, histologic grade, and clinical stage as predictors of clinical outcome Head Neck 2000, 22:489-497. 10.1002/ 1097-0347(200008)22:5<489::AID-HED8>3.0.CO;2-X 10897109
25. Carlinfante G Lazzaretti M Ferrari S Bianchi B Crafa P P53, bcl-2 and Ki-67 expression in adenoid cystic carcinoma of the palate. A clinico-pathologic study of 21 cases with long-term follow-up Pathol Res Pract 2005, 200:791-799. 10.1016/j.prp.2004.08.008 15792122
26. Greer RO Jr Said S Shroyer KR Marileila VG Weed SA Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma Oral Oncol 2007, 43:735-741. 10.1016/j.oraloncology.2006.09.007 17113340
27. Sakurai K Urade M Noguchi K Hashitani S Takaoka K Segawa E Kishimoto H Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIα expression in oral carcinoma Head Neck 2007, 29:1002-1009. 10.1002/hed.20627 17427971